View Item 

Show simple item record

State legislative trends related to biomarker testing

dc.contributor.authorSadigh, Gelareh
dc.contributor.authorGoeckner, Hilary Gee
dc.contributor.authorKazerooni, Ella A.
dc.contributor.authorJohnson, Bruce E.
dc.contributor.authorSmith, Robert A.
dc.contributor.authorAdams, Devon V.
dc.contributor.authorCarlos, Ruth C.
dc.date.accessioned2022-08-02T18:56:15Z
dc.date.available2023-09-02 14:56:14en
dc.date.available2022-08-02T18:56:15Z
dc.date.issued2022-08-01
dc.identifier.citationSadigh, Gelareh; Goeckner, Hilary Gee; Kazerooni, Ella A.; Johnson, Bruce E.; Smith, Robert A.; Adams, Devon V.; Carlos, Ruth C. (2022). "State legislative trends related to biomarker testing." Cancer (15): 2865-2870.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/173083
dc.publisherAmerican Cancer Society Cancer Action Network and LUNGevity Foundation
dc.publisherWiley Periodicals, Inc.
dc.subject.otherprior authorization
dc.subject.otherbiomarker testing
dc.subject.othercoverage
dc.subject.otherinsurance
dc.subject.otherlegislation
dc.titleState legislative trends related to biomarker testing
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/173083/1/cncr34271.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/173083/2/cncr34271_am.pdf
dc.identifier.doi10.1002/cncr.34271
dc.identifier.sourceCancer
dc.identifier.citedreferenceSheinson DM, Wong WB, Meyer CS, et al. Trends in use of next-generation sequencing in patients with solid tumors by race and ethnicity after implementation of the Medicare national coverage determination. JAMA Netw Open. 2021; 4: e2138219.
dc.identifier.citedreferenceHenderson R, Keeling P, French D, Smart D, Sullivan R, Lawler M. Cost-effectiveness of precision diagnostic testing for precision medicine approaches against non–small-cell lung cancer: a systematic review. Mol Oncol. 2021; 15: 2672 - 2687.
dc.identifier.citedreferencePennell NA, Mutebi A, Zhou Z-Y, et al. Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non–small-cell lung cancer using a decision analytic model. JCO Precis Oncol. 2019; 3: 1 - 9.
dc.identifier.citedreferenceChawla A, Peeples M, Li N, Anhorn R, Ryan J, Signorovitch J. Real-world utilization of molecular diagnostic testing and matched drug therapies in the treatment of metastatic cancers. J Med Econ. 2018; 21: 543 - 552.
dc.identifier.citedreferenceKehl KL, Lathan CS, Johnson BE, Schrag D. Race, poverty, and initial implementation of precision medicine for lung cancer. J Natl Cancer Inst. 2019; 111: 431 - 434.
dc.identifier.citedreferenceHealth equity in biomarker testing and targeted therapy. American Cancer Society Cancer Action Network. Published May 2021. Accessed December 3, 2021. https:// www.fightcancer.org/sites/default/files/FS%20Health%20Equity%20in%20BMT%20and%20Targeted%20Therapy_FINAL.pdf
dc.identifier.citedreferencePresley C, Soulos P, Chiang A, et al. Disparities in next generation sequencing in a population-based community cohort of patients with advanced non–small cell lung cancer. J Clin Oncol 2017; 35 ( 15 )(suppl): 6563.
dc.identifier.citedreferenceNorris RP, Dew R, Sharp L, et al. Are there socio-economic inequalities in utilization of predictive biomarker tests and biological and precision therapies for cancer? A systematic review and meta-analysis. BMC Med. 2020; 18: 282.
dc.identifier.citedreferenceImproving access to biomarker testing. American Cancer Society Cancer Action Network. Published September 28, 2020. Accessed December 6, 2021. https://www.fightcancer.org/policy-resources/improving-access-biomarker-testing
dc.identifier.citedreferencePayer Coverage Policies of Tumor Biomarker Testing. American Cancer Society Cancer Action Network and LUNGevity Foundation. Published September 2020. Accessed December 6, 2021. https://www.fightcancer.org/sites/default/files/ACS%20CAN%20and%20LUNGevity_Payer%20Coverage%20Policies%20of%20Tumor%20Biomarker%20Testing.pdf
dc.identifier.citedreferenceWong WB, Anina D, Lin CW, Adams DV. Alignment of health plan coverage policies for somatic multigene panel testing with clinical guidelines in select solid tumors. Per Med. 2022; 19: 171 - 180.
dc.identifier.citedreferenceGanesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019; 16: 361 - 375.
dc.identifier.citedreferenceAndre T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020; 383: 2207 - 2218.
dc.identifier.citedreferenceCasak SJ, Marcus L, Fashoyin-Aje L, et al. FDA approval summary: pembrolizumab for the first-line treatment of patients with MSI-H/dMMR advanced unresectable or metastatic colorectal carcinoma. Clin Cancer Res. 2021; 27: 4680 - 4684.
dc.identifier.citedreferenceNext generation sequencing (NGS) (90.2). Centers for Medicare & Medicaid Services. Published January 27, 2020. https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=372
dc.identifier.citedreferenceGenomic sequence analysis panels in the treatment of solid organ neoplasms. Centers for Medicare & Medicaid Services. Revised May 1, 2022. Accessed April 12, 2022. https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=37810&ver=17
dc.identifier.citedreferenceSheinson DM, Wong WB, Flores C, Ogale S, Gross CP. Association between Medicare’s national coverage determination and utilization of next-generation sequencing. JCO Oncol Pract. 2021; 17: e1774 - e1784.
dc.identifier.citedreferenceState Scorecard: State Medicaid Coverage Policy and Impact on Lung Cancer Outcomes. LUNGevity Foundation. Published March 2020. Accessed December 12, 2021. https://www.lungevity.org/sites/default/files/state-scorecards/LUNGevity-scorecard-030920.pdf
dc.identifier.citedreferenceFlowers ME. Flowers passes landmark legislation making biomarker testing accessible for Illinoisans. Illinois House Democratic Caucus Published September 27, 2021. Accessed December 17, 2021. https://ilhousedems.com/2021/09/27/flowers-passes-landmark-legislation-making-biomarker-testing-accessible-for-illinoisans/
dc.identifier.citedreferenceBill status of HB1779. Illinois General Assembly. Accessed December 17, 2021. https://www.ilga.gov/legislation/BillStatus.asp?DocNum=1779&GAID=16&DocTypeID=HB&SessionID=110&GA=102
dc.identifier.citedreferenceSenate Bill No. 84. Louisiana State Legislature. Accessed December 17, 2021. http://www.legis.la.gov/Legis/ViewDocument.aspx?d=1227189
dc.identifier.citedreferenceSenate Bill No. 535. California Legislative Information. Accessed December 17, 2021. https://leginfo.legislature.ca.gov/faces/billNavClient.xhtml?bill_id=202120220SB535
dc.identifier.citedreferenceBrown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care 2002; 40 (suppl 8): IV-104-17.
dc.identifier.citedreferenceShort PF, Moran JR, Punekar R. Medical expenditures of adult cancer survivors aged <65 years in the United States. Cancer. 2011; 117: 2791 - 2800.
dc.identifier.citedreferenceFinkelstein EA, Tangka FK, Trogdon JG, Sabatino SA, Richardson LC. The personal financial burden of cancer for the working-aged population. Am J Manag Care. 2009; 15: 801 - 806.
dc.identifier.citedreferenceThe Costs of Cancer. American Cancer Society Cancer Action Network. Published October 2020. Accessed February 8, 2022. https://www.fightcancer.org/sites/default/files/National%20Documents/Costs-of-Cancer-2020-10222020.pdf
dc.identifier.citedreferenceYabroff KR, Zhao J, Han X, Zheng Z. Prevalence and correlates of medical financial hardship in the USA. J Gen Intern Med. 2019; 34: 1494 - 1502.
dc.identifier.citedreferencePisu M, Kenzik KM, Oster RA, et al. Economic hardship of minority and non-minority cancer survivors 1 year after diagnosis: another long-term effect of cancer? Cancer. 2015; 121: 1257 - 1264.
dc.identifier.citedreferenceArbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non–small cell lung cancer: a review. JAMA. 2019; 322: 764 - 774.
dc.identifier.citedreferenceFebbo PG, Ladanyi M, Aldape KD, et al. NCCN task force report: evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw. 2011; 9 ( suppl 5 ): S1 - S32. quiz S33.
dc.identifier.citedreferenceMok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non–small-cell lung cancer in the ALEX study. Ann Oncol. 2020; 31: 1056 - 1064.
dc.identifier.citedreferenceJohn A, Yang B, Shah R. Clinical impact of adherence to NCCN guidelines for biomarker testing and first-line treatment in advanced non–small cell lung cancer (aNSCLC) using real-world electronic health record data. Adv Ther. 2021; 38: 1552 - 1566.
dc.identifier.citedreferenceGandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med. 2018; 378: 2078 - 2092.
dc.identifier.citedreferenceCarbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in stage IV or recurrent non–small-cell lung cancer. N Engl J Med. 2017; 376: 2415 - 2426.
dc.identifier.citedreferenceSurvey findings summary: understanding provider utilization of cancer biomarker testing across cancers. American Cancer Society Cancer Action Network. Published December 2021. Accessed December 12, 2021. https:// www.fightcancer.org/sites/default/files/national_documents/provider_utilization_of_biomarker_testing_polling_memo_dec_2021.pdf
dc.identifier.citedreferenceMack PC, Klein MI, Ayers KL, Zhou X, Guin S, Fink M, Rossi M, Ai-Kateb H, O’Connell T, Hantash FM, Oh WK, Newman S, Schadt EE, Chen R, Hirsch FR Targeted next-generation sequencing reveals exceptionally high rates of molecular driver mutations in never-smokers with lung adenocarcinoma. Oncologist. 2022; oyac035.
dc.identifier.citedreferenceLee SH, Lee B, Shim JH, et al. Landscape of actionable genetic alterations profiled from 1,071 tumor samples in Korean cancer patients. Cancer Res Treat. 2019; 51: 211 - 222.
dc.identifier.citedreferenceFox AH, Jett JR, Roy UB, et al. Knowledge and practice patterns among pulmonologists for molecular biomarker testing in advanced non–small cell lung cancer. Chest. 2021; 160: 2293 - 2303.
dc.identifier.citedreferenceMehta A, Vasudevan S, Sharma SK, et al. Biomarker testing for advanced lung cancer by next-generation sequencing; a valid method to achieve a comprehensive glimpse at mutational landscape. Appl Cancer Res. 2020; 40: 4. doi: 10.1186/s41241-020-00089-8
dc.identifier.citedreferenceFreedman AN, Klabunde CN, Wiant K, et al. Use of next-generation sequencing tests to guide cancer treatment: results from a nationally representative survey of oncologists in the United States. JCO Precis Oncol. 2018; 2: 1 - 13.
dc.identifier.citedreferenceMileham KF, Schenkel C, Bruinooge SS, et al. Defining comprehensive biomarker-related testing and treatment practices for advanced non–small-cell lung cancer: results of a survey of U.S. oncologists. Cancer Med. 2022; 11: 530 - 538.
dc.identifier.citedreferenceDieguez G, Carioto J. The landscape of biomarker testing coverage in the United States. Milliman, Inc. Published February 15, 2022. Accessed April 8, 2022. https://www.milliman.com/en/insight/the-landscape-of-biomarker-testing-coverage-in-the-US
dc.identifier.citedreferenceDesai K, Hooker G, Gilbert K, Cropper C, Metcalf R, Kachroo S. Real-world trends in costs of next generation sequencing (NGS) testing in U.S. setting. J Clin Oncol. 2021; 39: e18824.
dc.identifier.citedreferenceDalal AA, Guerin A, Mutebi A, Culver KW. Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer. J Med Econ. 2018; 21: 649 - 655.
dc.identifier.citedreferencePisu M, Azuero A, Meneses K, Burkhardt J, McNees P. Out of pocket cost comparison between Caucasian and minority breast cancer survivors in the Breast Cancer Education Intervention (BCEI). Breast Cancer Res Treat. 2011; 127: 521 - 529.
dc.identifier.citedreferenceMessner DA, Al Naber J, Koay P, et al. Barriers to clinical adoption of next generation sequencing: perspectives of a policy Delphi panel. Appl Transl Genom. 2016; 10: 19 - 24.
dc.identifier.citedreferenceLu CY, Loomer S, Ceccarelli R, et al. Insurance coverage policies for pharmacogenomic and multi-gene testing for cancer. J Pers Med. 2018; 8: 10.
dc.identifier.citedreferenceTrosman JR, Douglas MP, Liang SY, et al. Insights from a temporal assessment of increases in US private payer coverage of tumor sequencing from 2015 to 2019. Value Health. 2020; 23: 551 - 558.
dc.identifier.citedreferenceSurvivor views: biomarker testing. American Cancer Society Cancer Action Network. Published September 28, 2020. Accessed April 7, 2022. https:// www.fightcancer.org/sites/default/files/Survivor%20Views%20Biomarker%20Testing%20Polling%20Memo.pdf
dc.identifier.citedreferenceSeo MK, Cairns J. Do cancer biomarkers make targeted therapies cost-effective? A systematic review in metastatic colorectal cancer. PLoS One. 2018; 13: e0204496.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr34271.pdf
Size:
179.1KB
Format:
PDF
View/Open
Name:
cncr34271_am.pdf
Size:
444.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.